LEUKEMIA, LYMPHOMA & MYELOMA EVALUATION

Advanced Blood Cancer Care in China

Blood cancers—including leukemia, lymphoma, and multiple myeloma—affect the bone marrow and immune system. When standard chemotherapy stops working or cancer returns, patients need advanced options. China has become a global leader in cellular immunotherapy, performing more CAR-T cell infusions and half-matched bone marrow transplants than any other country, offering real hope and lasting remissions for difficult cases.

  • Leukemia, Lymphoma & Multiple Myeloma at Any Stage
  • Cancer That Has Returned or Resisted Prior Chemotherapy
  • Patients Seeking Advanced Living Cell Therapy (CAR-T) or Transplant
  • World-Leading Cell Therapy Units with Ultra-Clean Sterile Rooms
  • Experienced Specialists with Thousands of Successful Cell Infusions
  • Dedicated English-Speaking Medical Coordinators at Your Bedside

ADVANCED CELLULAR & TARGETED OPTIONS

Key Blood Cancer Treatments in China

World-leading CAR-T cell therapy, half-matched bone marrow transplants, and next-generation targeted medications.

CAR-T Cell Therapy

Your own immune cells are collected, trained in a lab to recognize and attack blood cancer cells, and returned to your body to hunt down tumors.
Learn More

Bone Marrow Transplant

Using the world-renowned "Beijing Protocol", almost any family member (even a 50% match) can safely donate stem cells, eliminating the wait for an exact donor match.
Learn More

Targeted Antibody Biologics

Smart medications that stick directly to cancer cells like homing beacons, helping destroy the cancer while leaving healthy blood cells unharmed.
Learn More

WHY CHOOSE US

Why Choose China Cancer Help for Blood Cancer Care

A specialized clinical continuum connecting international patients directly with China’s top national hematology institutes.

You are not directed to an unvetted broker network. We connect you directly with China’s premier Grade 3A national hematology institutes that treat the world’s largest volumes of relapsed and refractory leukemia, lymphoma, and multiple myeloma. Patients gain direct access to advanced CAR-T cellular therapies, world-renowned half-matched stem cell transplants (Beijing Protocol), and innovative targeted antibodies often available years ahead of international approvals.

Before you make any travel arrangements, a specialized hematology tumor board evaluates your complete pathology, flow cytometry, and genetic panel to confirm clinical eligibility and recommend a clear protocol. All medical care is billed directly by accredited public tertiary hospitals under transparent, published fee schedules, with continuous English bedside coordination from admission to post-discharge care.

CASE EVALUATION PATHWAY

A Structured Pathway from Records to Care

A transparent, four-stage continuum connecting preliminary clinical evaluation to official hospital acceptance, specialized inpatient care, and ongoing continuity.

01. Submit Records Online

Upload pathology reports, biomarker NGS profiles, and imaging scans through our confidential clinical intake portal.

02. Remote MDT Review

National Clinical Research Center oncology boards evaluate eligibility, target expression, and formulate a customized protocol.

03. Visa & Admission

Receive official hospital medical invitation letters, transparent pricing schedules, and expedited department admission.

04. Treatment & Follow-up

Inpatient cellular or particle therapy in ISO-GMP cleanrooms with dedicated bilingual escorts and remote post-discharge care.

PATIENT FAQS

Frequently Asked Questions

Key clinical, financial, and logistical insights for international Blood Cancer patients considering advanced treatment in China.

Patients with relapsed or refractory B-cell acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma who have progressed after standard therapies can be evaluated for CD19, CD22, or BCMA directed CAR-T cells.
The Beijing Protocol is a globally recognized half-matched (haploidentical) stem cell transplantation method allowing parents, children, or siblings who are only a 50% HLA match to successfully serve as donors with outcomes equal to identical donor matches.
Patients generally stay 3 to 4 weeks, including cell collection, bridging therapy if necessary, infusion, and careful monitoring in sterile laminar flow rooms.
Tertiary hematology centers maintain dedicated intensive care units and standardized protocols to promptly manage cytokine release syndrome (CRS) and neurotoxicity.

LEUKEMIA, LYMPHOMA & MYELOMA CLINICAL ASSESSMENT

Request a Confidential Case Review for Blood Cancer

Share your pathology reports, blood tests, and prior treatment records for a thorough, free evaluation by our specialist medical team.

    Blood Cancer